Gallbladder Cancer - Pipeline Review, H1 2020

May 2020 | 695 pages | ID: G786700467AEN
Global Markets Direct

Abstracts

Gallbladder Cancer - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer – Pipeline Review, H1 2020, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 8, 20, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Gallbladder Cancer - Overview
Gallbladder Cancer - Therapeutics Development
Gallbladder Cancer - Therapeutics Assessment
Gallbladder Cancer - Companies Involved in Therapeutics Development
Gallbladder Cancer - Drug Profiles
Gallbladder Cancer - Dormant Projects
Gallbladder Cancer - Discontinued Products
Gallbladder Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Gallbladder Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Gallbladder Cancer - Pipeline by 4SC AG, H1 2020
Gallbladder Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020
Gallbladder Cancer - Pipeline by Alligator Bioscience AB, H1 2020
Gallbladder Cancer - Pipeline by Almac Discovery Ltd, H1 2020
Gallbladder Cancer - Pipeline by Alphamab Oncology, H1 2020
Gallbladder Cancer - Dormant Projects, H1 2020
Gallbladder Cancer - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Gallbladder Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4SC AG
Advenchen Laboratories LLC
Alligator Bioscience AB
Almac Discovery Ltd
Alphamab Oncology
Andes Biotechnologies
Apexian Pharmaceuticals Inc
Apollomics Inc
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Bristol-Myers Squibb Co
Delta-Fly Pharma Inc
Diverse Biotech Inc
Eisai Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Fujifilm Holdings Corp
Hutchison MediPharma Ltd
Infinity Pharmaceuticals Inc
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Karus Therapeutics Ltd
Kringle Pharma Inc
Leap Therapeutics Inc
Lokon Pharma AB
Merck & Co Inc
Mina Therapeutics Ltd
Molecular Templates Inc
NuCana Plc
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Rafael Pharmaceuticals Inc
Shanghai Haihe Biopharma Co Ltd
Shanghai Junshi Bioscience Co Ltd
Sinocelltech Ltd
SMT bio Co Ltd
Taiho Oncology Inc
TOT Biopharm Co Ltd
Turning Point Therapeutics Inc
VasGene Therapeutics Inc
XuanZhu Pharma Co Ltd
Zymeworks Inc